GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.
Trial recruiting looks to tap online community leaders
An Italian court backs the anti-trust’s stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court’s new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer’s treatment to Phase-III.
Point-of-care messaging growth surpasses DTC growth: study
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
Insulin pump approval sets up showdown with Medtronic
GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir’s inhalable migraine medication.
BMS proposed HCV therapy gets cold shoulder from regulators